Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMP1734 |
| Synonyms | |
| Therapy Description |
IMP1734 selectively inhibits PARP1, which potentially induces tumor cell cytotoxicity and inhibits tumor growth (Eur J Cancer 211 (2024): 114870). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMP1734 | IMP-1734|IMP 1734|EIK1003|EIK 1003|EIK-1003 | PARP-1 Inhibitor 13 | IMP1734 selectively inhibits PARP1, which potentially induces tumor cell cytotoxicity and inhibits tumor growth (Eur J Cancer 211 (2024): 114870). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06253130 | Phase Ib/II | IMP1734 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | DNK | CAN | AUS | 2 |